Finding weaknesses in cancer cells that produce too much Mdm2
Identifying the vulnerabilities in Mdm2 overexpressing cancer cells
This study is looking at how some cancer cells can escape the body's defenses by making too much of a protein called Mdm2, and it aims to find their weaknesses so that new treatments can be developed to help patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10886612 on NIH RePORTER |
What this research studies
This research investigates how certain cancer cells that overproduce a protein called Mdm2 can evade the body's natural tumor suppression mechanisms, particularly those involving the p53 protein. Using advanced techniques like CRISPR, the researchers aim to identify the specific vulnerabilities of these cancer cells, which could lead to new treatment strategies. The project involves both preliminary and secondary genetic screens to pinpoint factors that allow these cells to survive despite high levels of Mdm2, which are typically harmful to normal cells. Patients may benefit from insights gained in this research that could inform future therapies targeting Mdm2 overexpression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit high levels of Mdm2 expression.
Not a fit: Patients whose cancers do not involve Mdm2 overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for cancers characterized by Mdm2 overexpression.
How similar studies have performed: Previous research has shown promise in targeting Mdm2 and related pathways, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Pant, Vinod — University of Tx Md Anderson Can Ctr
- Study coordinator: Pant, Vinod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.